Sandoz to invest $80 million in Boucherville facilities
Over 100 new jobs to be created
Sandoz Canada announced that it will invest $80 million in its Boucherville facilities as demand for its generic sterile injectable pharmaceuticals continues to grow in Canada and around the world. In addition to more than 100 new positions created in 2006, 100 additional jobs will be created in Canada over the next two years.
The $80 million investment includes the construction of a second manufacturing site; the expansion of the drug development laboratory, purchase of state-of-the-art laboratory equipment and expansion of the quality control laboratory; new manufacturing equipment for the existing manufacturing plant; and the acquisition of additional land and building adjacent to the head office.
The investment will translate into the addition of 40,000 square feet (3,716 square meters) of manufacturing space, 10,500 square feet (975 square meters) of warehousing space and 17,000 square feet (1,579 square meters) for administrative support. In addition, the current manufacturing site will undergo improvements to ensure that it maintains its position as a top-performing production facility. By completion of this project, the production capacity will have been increased by 66 per cent.
According to the company, the Boucherville site is the largest small-volume injectable drug production facility in Canada and within the Novartis Group of companies. Its product portfolio includes over 100 molecules such as narcotics, sedatives, antibiotics, ophthalmics, hormone treatments, corticosteroids and cardiology drugs. In addition, Boucherville is a worldwide center of excellence for the development of sterile injectable pharmaceuticals within Sandoz.
PLIVA d.d. announced that an agreement has been signed with Novartis' generics division, Sandoz, for the purchase of its Spanish subsidiary Uso Racional S.L (UR) for a total cash consideration of EUR 21.5m. With expected sales of about EUR 12m in 2006, UR represents a well known and establi ... more
Lek, a Sandoz company, opened a new plant at its Lendava site for the final phases of isolation of potassium clavulanate, which is the key ingredient of Amoksiklav, one of Lek's leading products that ranks among leading products also in Sandoz. Regular production of potassium clavulanate be ... more